Select a medication above to begin.
Saxenda
liraglutide
Black Box Warnings .
Thyroid C-cell Tumor Risk
contraindicated in pts w/ medullary thyroid carcinoma (MTC) hx or family hx, or in pts w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise pts of potential MTC risk and thyroid tumor sx (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness)
Adult Dosing .
Dosage forms: INJ (pen): 6 mg per mL
weight management, chronic
- [3 mg SC qd]
- Start: 0.6 mg SC qd x1wk, then incr. dose by 0.6 mg/day qwk to target 3 mg SC qd; Max: 3 mg/day; Info: for pts w/ BMI >30 kg/m^2 or >27 kg/m^2 w/ wt-related comorbidity; may delay dose titration x1wk if intolerance; D/C if wt loss <4% after 16wk or if 3 mg SC qd not tolerated; retitrate from 0.6 mg SC qd if tx interrupted for >3 days
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ (pen): 6 mg per mL
weight management, chronic
- [12 yo and older, >60 kg]
- Dose: 3 mg SC qd; Start: 0.6 mg SC qd x1wk, then may incr. dose by 0.6 mg/day qwk to target 3 mg SC qd; Max: 3 mg/day; Info: for pts w/ BMI corresponding to >30 kg/m^2 for adults; may decr. maint. dose to 2.4 mg SC qd if 3 mg SC qd not tolerated; D/C if BMI change <1% after 12wk on maint. dose or if 2.4 mg SC qd not tolerated; retitrate from 0.6 mg SC qd if tx interrupted for >3 days
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]